Modeled onset-failure cases are PK→PD scenarios in which the concentration-time trajectory does not reach the predefined PD threshold within the interpretation window. “Onset failure” therefore denotes a modeling phenomenon, not real-world failure. In PK geometry, absorption rate, absorption timing, gastric emptying, solubility, distribution loading, redistribution timing, and first-pass metabolism determine how rapidly systemic exposure develops. Modeled external modifiers, including food delay, fatty-meal delay, alcohol delay, and dose-dependent absorption variability, can shift the rising phase, flatten its slope, or reduce early systemic entry. Tmax and Cmax describe modeled peak timing and amplitude, while neither parameter alone defines onset. The PD layer transforms exposure through threshold placement, binding sensitivity, coupling geometry, and noise bands. If the transformed trajectory remains below the modeled boundary, no threshold-crossing interval appears. This creates a non-crossing onset region whose duration and position depend on the specified PK and PD parameters. Link to onset overview.
PK mechanisms behind modeled onset-failure cases arise from changes in the timing, magnitude, and shape of systemic exposure. A lower absorption rate flattens the rising phase, while later absorption timing shifts the trajectory rightward. Slower modeled gastric emptying delays entry into the absorption window, and lower solubility can reduce the fraction available for systemic absorption. Greater distribution loading can reduce early central concentration while redistribution timing alters subsequent recovery of central exposure. Stronger first-pass metabolism reduces modeled systemic entry before the concentration-time curve develops. Modeled food and fatty-meal delays can shift input timing and alter the curvature of the ascending phase. A modeled alcohol delay can similarly modify gastric emptying and early input. Dose-dependent absorption variability can widen the set of modeled trajectories. Lower Cmax geometry may leave the curve below threshold, while concentration-dependent clearance can steepen or reshape decline and limit persistence within the interpretation window. Link to food delay and alcohol delay.
PD mechanisms determine whether a given PK trajectory is translated into modeled onset. Higher threshold placement creates a larger concentration requirement before the onset region is entered, so a moderately rising PK curve may remain below the boundary. Lower binding sensitivity reduces the magnitude of the transformed signal for a given concentration change. Shallow coupling geometry can compress the transition between concentration and PD coordinates, reducing the apparent movement toward threshold. Wide PD noise bands can also broaden uncertainty around the mapped signal and make threshold entry less sharply defined. When PK trajectories are weakened by modeled food delay, modeled alcohol delay, or dose-dependent absorption variability, these PD properties can further reduce or delay threshold crossing. An amplifying coupling geometry can instead magnify small concentration differences, whereas a compressive geometry can preserve a below-threshold trajectory. Thus, modeled onset failure is produced by the interaction of PK trajectory geometry with PD transformation parameters, not by a single isolated parameter. Link to onset speed difference.
Modeled onset failure can emerge when the ascending PK trajectory is too shallow, too delayed, or too attenuated to enter the predefined PD threshold region. A lower absorption rate decreases the slope of systemic entry, extending the interval before concentrations approach the modeled boundary. Later absorption timing shifts the entire rising phase toward later times. Slower gastric emptying delays the arrival of drug into the effective absorption window, while reduced solubility can lower the available fraction for absorption. Increased distribution loading can divert early exposure from the central compartment, and redistribution timing determines when that exposure returns or equilibrates. Stronger first-pass metabolism reduces systemic availability before the central concentration develops. These mechanisms can act independently or combine, producing trajectories with delayed Tmax, reduced Cmax, or altered curvature. In each case, “failure” means non-crossing of a predefined model threshold within a specified window, rather than a statement about real-world effects. Link to absorption rate.
Modeled external factors modify PK geometry rather than representing clinical causes or guidance. A food-delay parameter can shift absorption timing and alter the slope of the rising phase; a fatty-meal-delay parameter can represent a larger modeled shift associated with slower gastric emptying and altered dissolution or input timing. An alcohol-delay parameter can similarly encode a modeled change in gastric emptying or early absorption. Dose-dependent absorption variability can generate multiple simulated trajectories from different input conditions, widening the range of Tmax and Cmax geometries. When these modifiers are combined with lower absorption rate, stronger first-pass loss, or greater distribution loading, some trajectories may remain below the PD threshold for the full modeled window. The resulting non-crossing pattern is therefore a property of parameterized PK simulation. It does not establish a real-world delay, failure state, recommendation, or expected outcome; it only describes how specified external-modifier parameters reshape modeled exposure. Link to food delay.
| PK Domain | Failure Effect | Link |
|---|---|---|
| Absorption Rate | Insufficient rising-phase slope. | absorption rate |
| Gastric Emptying | Delayed input arrival. | gastric emptying |
| Food Delay | Modeled dissolution slowdown. | food delay |
Threshold placement determines the concentration or transformed-signal level required for a modeled trajectory to enter the onset region. If the threshold is positioned above the maximum of a simulated concentration-effect trajectory, the model produces no crossing during the defined window. If the threshold lies near the trajectory apex, small changes in absorption timing, Cmax geometry, or clearance can move the crossing boundary substantially. Threshold placement therefore interacts with Tmax and Cmax rather than operating independently. A later threshold crossing may result from a right-shifted PK curve, while complete non-crossing occurs when the transformed signal remains below the boundary. In this framework, onset predictability concerns the stability of the modeled crossing location under parameter variation, not real-world predictability. Differences among simulated trajectories can therefore be represented as changes in crossing time, crossing presence, or crossing absence. The resulting classification remains entirely dependent on the predefined threshold and interpretation window. Link to onset predictability.
Binding sensitivity, coupling geometry, and PD noise bands determine how strongly modeled concentration differences are expressed in the PD coordinate. Lower binding sensitivity can compress the transformed signal, so a given PK rise produces a smaller movement toward threshold. Shallow coupling geometry can make the concentration-to-PD relationship less steep around the relevant region, while a steeper geometry can magnify small concentration changes. Wide noise bands introduce a broader modeled interpretation region around the central PD trajectory, making the exact threshold boundary less sharply resolved. These mechanisms can convert a modest PK attenuation into a modeled non-crossing interval or, under different parameterization, preserve a threshold crossing despite similar PK exposure. PD variability therefore does not replace PK geometry; it transforms and qualifies its interpretation. In modeled onset-failure cases, the decisive feature is the joint relationship between exposure trajectory, binding response, coupling function, threshold placement, and noise representation within the predefined analysis window. Link to onset variability.
| PD Domain | Failure Effect | Link |
|---|---|---|
| Threshold Placement | Non-entry region. | onset overview |
| Binding Sensitivity | Compression of PK signal. | onset variability |
| Coupling Geometry | Slope-driven suppression. | onset vs peak |
Modeled sildenafil can be represented as showing onset non-crossing when delayed absorption, stronger modeled first-pass loss, and food-delay parameters collectively reduce or postpone early systemic exposure. A slower absorption rate can flatten the ascending curve, while delayed absorption timing shifts Tmax geometry later. A first-pass parameter can lower the modeled amount reaching systemic circulation, reducing Cmax geometry without necessarily changing the basic input shape. Food-delay parameters can further shift input timing through modeled gastric-emptying effects. Distribution loading and redistribution timing can then modify the central concentration available to the PD mapping. If the resulting trajectory remains below the specified threshold, the model labels the interval as non-crossing. This representation is specific to the chosen parameter set and does not assert a real-world onset outcome. The comparison is therefore about modeled geometry: how changes in input timing, systemic availability, central exposure, and PD threshold placement combine to generate or remove a simulated crossing. Link to why sildenafil onset differs.
Modeled vardenafil can be represented as showing onset non-crossing when lower modeled solubility, delayed gastric emptying, and alcohol-delay parameters jointly reduce or postpone the early exposure trajectory. A solubility parameter can limit the material entering the absorbable state, while delayed gastric emptying shifts the arrival of that material into the modeled absorption window. An alcohol-delay parameter can add another timing modification to early input. The resulting trajectory may show a later Tmax, lower Cmax, or a changed rising-phase curvature. Distribution loading and redistribution timing can further separate early central exposure from later compartmental equilibration. If the transformed PD signal remains below the specified threshold, the model contains a non-crossing interval. This is a compound-specific simulation construct rather than a statement about real-world onset. The mechanistic comparison concerns how the selected parameterization maps solubility, gastrointestinal timing, systemic entry, distribution, and PD threshold placement into different modeled trajectory geometries. Link to why levitra onset differs.
PD mapping can amplify or suppress modeled onset-failure differences between sildenafil and vardenafil by changing how each PK trajectory is translated into the PD coordinate. If one simulated curve has a lower Cmax or later Tmax, a high threshold may convert that difference into complete non-crossing, whereas a lower threshold may preserve a crossing. Binding sensitivity controls the magnitude of the transformed response to concentration differences, and coupling geometry determines whether those differences are compressed or expanded around threshold. PD noise bands further affect how sharply crossing is represented. Consequently, two compounds with distinct PK geometries can show similar modeled onset-failure intervals under one PD parameterization and different intervals under another. The comparison remains a mathematical mapping exercise: absorption, solubility, gastric timing, first-pass loss, distribution, and clearance define the PK input, while threshold placement and PD transformation define its interpretation. No modeled crossing pattern is treated as evidence of real-world effectiveness or failure. Link to onset speed difference.
| Compound | Failure Behavior | Link |
|---|---|---|
| Sildenafil | Absorption-driven non-crossing. | why sildenafil onset differs |
| Vardenafil | Solubility-driven non-crossing. | why levitra onset differs |
| Mapping | Amplifies differences. | onset speed difference |
Modeled onset failure occurs when the PK→PD trajectory remains below the predefined onset threshold throughout the specified interpretation window. The mechanism can involve a shallow absorption phase, delayed input timing, slower gastric emptying, reduced solubility, greater distribution loading, altered redistribution timing, stronger first-pass metabolism, or reduced systemic availability. These parameters can lower Cmax, shift Tmax, or reshape the rising phase so that the modeled concentration does not enter the threshold region. The PD layer can reinforce this pattern through higher threshold placement, lower binding sensitivity, compressive coupling geometry, or broad noise representation. Onset failure is therefore a property of the combined parameter set and analysis window. It does not identify a real-world failure state, effectiveness level, or expected patient outcome. Different parameter combinations can generate the same non-crossing geometry.
Modeled PK mechanisms include absorption rate, absorption timing, gastric emptying, solubility, distribution loading, redistribution timing, first-pass metabolism, bioavailability, Tmax geometry, Cmax geometry, and concentration-dependent clearance. A slower absorption rate can flatten the rising phase, while delayed absorption timing or slower gastric emptying can shift it later. Lower solubility can reduce material available for systemic entry. Greater distribution loading can reduce early central exposure, while redistribution timing changes later central recovery. Stronger first-pass metabolism can reduce systemic availability before the concentration curve develops. Tmax and Cmax describe the resulting peak geometry rather than defining onset. Concentration-dependent clearance can reshape the trajectory and alter how long it remains near threshold. Combined mechanisms may leave the simulated curve below the PD boundary. This defines the modeled failure geometry.
Modeled PD mechanisms include threshold placement, binding sensitivity, coupling geometry, and PD noise bands. A higher threshold requires a greater transformed signal before the onset region is entered. Lower binding sensitivity can reduce the PD response generated by a given concentration, while shallow or compressive coupling geometry can attenuate movement toward threshold. Noise bands can broaden the modeled interpretation around the central trajectory, making the crossing boundary less sharply defined. These parameters interact with PK geometry rather than replacing it. A trajectory with reduced Cmax or delayed Tmax may cross under one threshold configuration but remain below threshold under another. Stronger coupling can preserve a crossing for the same PK input that fails under compressive mapping. Onset failure therefore identifies a modeled non-crossing relationship between PK exposure and PD interpretation, not a clinical event or real-world effectiveness claim in the model.
External modeled factors contribute by modifying PK parameters inside the simulation. Food delay can shift absorption timing or alter the rising-phase slope, while a fatty-meal-delay parameter can represent a modeled change in gastric emptying, dissolution, or input timing. An alcohol-delay parameter can encode a modeled alteration in early gastrointestinal input. Dose-dependent absorption variability can generate simulated trajectories with different absorption rates, timing, Tmax values, and Cmax values. When these modifiers combine with distribution loading, first-pass metabolism, or concentration-dependent clearance, some trajectories may remain below threshold. Their role is mathematical: each factor changes specified PK inputs. These modeled modifiers do not constitute guidance, recommendations, or claims about real-world settings. A non-crossing trajectory indicates that the selected parameter combination did not enter the predefined PD threshold region within the modeled window.
PK→PD mapping explains modeled onset-failure differences by separating exposure geometry from its interpretation. PK parameters determine how rapidly systemic concentration rises, how high the curve becomes, when Tmax occurs, and how distribution and clearance reshape the trajectory over time. The PD layer maps that trajectory through binding sensitivity, coupling geometry, threshold placement, and noise bands. Two simulated compounds can have different PK curves but similar non-crossing behavior if the PD mapping compresses their differences. Conversely, modest PK differences can produce larger differences when the threshold lies near the trajectory apex or coupling is steep. The resulting interval depends on the complete parameter set and interpretation window. This framework treats sildenafil and vardenafil as modeled systems for mathematical comparison. It does not convert non-crossing geometry into real-world effectiveness or patient-outcome claims.